

Effect of arterial administration of high-molecular-weight  
lipid lymphographic agent on hepatoma: a preliminary

European Journal of Cancer & Clinical Oncology

19, 1053-1065

DOI: [10.1016/0277-5379\(83\)90028-7](https://doi.org/10.1016/0277-5379(83)90028-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on smancs. The Protein Journal, 1984, 3, 181-193.	1.1	109
2	Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer, 1984, 54, 2367-2374.	2.0	226
4	Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer, 1985, 56, 751-757.	2.0	150
5	Small mass lesions in cirrhosis: Transition from benign adenomatous hyperplasia to hepatocellular carcinoma?. Journal of Gastroenterology and Hepatology (Australia), 1986, 1, 3-14.	1.4	51
6	Early recognition of hepatocellular carcinoma. Hepatology, 1986, 6, 729-738.	3.6	305
7	Primary liver cancer. Digestive Diseases and Sciences, 1986, 31, 133-146.	1.1	71
8	Treatment of Hepatocellular Carcinoma by Transarterial Injection of Anticancer Agents in Iodized Oil Suspension or of Radioactive Iodized Oil Solution. Acta Radiologica: Diagnosis, 1986, 27, 139-147.	0.4	78
9	Intra-Arterial Injection of Adriamycin/Mitomycin C Lipiodol Suspension in Liver Metastases. Acta Radiologica, 1987, 28, 275-280.	0.5	36
10	Preparation of and drug release from W/O/W type double emulsions containing anticancer agents using an oily lymphographic agent as an oil phase.. Chemical and Pharmaceutical Bulletin, 1987, 35, 3375-3381.	0.6	29
11	Lipid Emulsions as Drug Delivery Systems. Annals of the New York Academy of Sciences, 1987, 507, 75-88.	1.8	137
12	8 Chemotherapy and radiotherapy of malignant hepatic tumours. Bailliere's Clinical Gastroenterology, 1987, 1, 151-169.	0.9	6
13	Anticancer effects of arterial administration of the anticancer agent SMANCS with lipiodol on metastatic lymph nodes. Cancer, 1987, 59, 1560-1565.	2.0	46
14	A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer, 1987, 60, 1194-1203.	2.0	240
15	Intraarterial chemotherapy with lipid contrast medium for hepatic malignancies in infants. Cancer, 1987, 60, 2886-2890.	2.0	25
16	NECROSIS OF PORTAL TUMOR EMBOLUS OF HEPATOCELLULAR CARCINOMA BY LIPIODOL TRANSCATHETER CHEMOEMBOLIZATION. A Case Report. Pathology International, 1988, 38, 1363-1367.	0.6	2
17	Plasma abnormal prothrombin (Des-Î <sup>3</sup> -carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer, 1988, 61, 1621-1628.	2.0	107
18	Involvement of the Kinin-generating Cascade in Enhanced Vascular Permeability in Tumor Tissue. Japanese Journal of Cancer Research, 1988, 79, 1327-1334.	1.7	150
19	Computed tomography detection of small daughter nodules in hepatocellular carcinoma after iodized oil infusion into the hepatic artery. The Journal of Computed Tomography, 1988, 12, 129-134.	0.1	11

#	ARTICLE	IF	CITATIONS
20	Clinical trials in primary hepatocellular carcinoma: current status and future directions. <i>Cancer Treatment Reviews</i> , 1988, 15, 1-31.	3.4	196
21	Improvement of Pharmacological Properties of Protein-Drugs by Tailoring with Synthetic Polymers. <i>Journal of Bioactive and Compatible Polymers</i> , 1988, 3, 27-43.	0.8	30
22	Treatment of Liver Metastases by Arterial Injection of Adriamycin/Mitomycin C Lipiodol Suspension. <i>Acta Radiologica</i> , 1989, 30, 603-608.	0.5	13
23	Transcatheter Arterial Chemotherapy Using Doxorubicin, Iodized Oil and Gelfoam Embolization in Hepatocellular Carcinoma. <i>Acta Radiologica</i> , 1989, 30, 415-418.	0.5	38
24	In Vivo Microscopy of the Liver after Injection of Lipiodol into the Hepatic Artery and Portal Vein in the Rat. <i>Acta Radiologica</i> , 1989, 30, 419-425.	0.5	65
25	Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic-acid-styrene)-conjugated neocarzinostatin. <i>Cancer Immunology, Immunotherapy</i> , 1989, 30, 97-104.	2.0	11
26	Transcatheter arterial chemoembolization with anticancer drug in iodized oil for primary hepatic carcinoma. <i>CardioVascular and Interventional Radiology</i> , 1989, 12, 181-187.	0.9	1
27	Tissue distribution of cisplatin after hepatic arterial injection of a cisplatin-lipiodol suspension containing phosphatidylcholine to rabbits carrying VX-2 hepatic carcinoma. <i>Pharmaceutical Research</i> , 1989, 06, 342-345.	1.7	4
28	A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma. <i>Hepatology</i> , 1989, 10, 98-102.	3.6	204
29	New method of photosensitizer accumulation for photodynamic therapy in an experimental liver tumor. <i>Lasers in Surgery and Medicine</i> , 1989, 9, 254-263.	1.1	37
30	Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. <i>Cancer</i> , 1989, 64, 1586-1594.	2.0	133
31	Intraarterial infusion of 5-fluoro-2-deoxyuridine-C8 dissolved in a lymphographic agent in malignant liver tumors. A preliminary report. <i>Cancer</i> , 1989, 64, 2437-2444.	2.0	30
32	Cooperative study on arterial regional chemotherapy for primary liver cancer in Hokkaido. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, S17-S20.	1.1	3
33	Transcatheter arterial embolization using iodized oil (lipiodol) mixed with an anticancer drug for the treatment of hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, S33-S36.	1.1	30
34	Combination chemoembolization therapy for hepatocellular carcinoma: mainly, using cisplatin (CDDP). <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, S42-S44.	1.1	18
35	Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, S54-S58.	1.1	31
36	Significance of transcatheter chemoembolization combined with surgical resection for hepatocellular carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, S90-S95.	1.1	26
37	Adriamycin-Lipiodol suspension for i. a. chemotherapy of hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, 238-242.	1.1	21

#	ARTICLE	IF	CITATIONS
38	Efficacy of Two-route Chemotherapy Using Intraperitoneal Neocarzinostatin and Its Antidote, Intravenous Tiopronin, for Peritoneally Disseminated Tumors in Mice. Japanese Journal of Cancer Research, 1989, 80, 283-289.	1.7	7
39	Differential Neutralizing Effect of Tiopronin on the Toxicity of Neocarzinostatin and SMANCS: A New Rescue Cancer Chemotherapy. Japanese Journal of Cancer Research, 1989, 80, 394-399.	1.7	4
40	Effect of chemoembolization of albumin microspheres containing mitomycin C on AH 272 liver metastasis in rats. International Journal of Pharmaceutics, 1989, 54, 27-32.	2.6	4
41	Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology, 1989, 97, 965-971.	0.6	186
42	Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, smancs, in an oily formulation. Pharmaceutical Research, 1990, 07, 852-855.	1.7	22
43	Transcatheter arterial embolization in unresectable hepatocellular carcinoma. CardioVascular and Interventional Radiology, 1990, 13, 135-139.	0.9	79
44	Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma. Cancer, 1990, 65, 913-919.	2.0	41
45	Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer, 1990, 66, 1897-1903.	2.0	111
46	Polymer Drugs and Polymeric Drugs, Part VII*: Antitumor Conjugated Polymeric Drugs Consisting of 5-Fluorouracil and Polyanionic Polymers. Journal of Bioactive and Compatible Polymers, 1990, 5, 53-64.	0.8	3
47	Prognostic Factors in Liver Metastases after Transcatheter Arterial Embolization or Arterial Infusion. Acta Radiologica, 1990, 31, 269-274.	0.5	12
48	Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. Journal of Hepatology, 1990, 11, 349-353.	1.8	52
49	New aspects of polymer drugs. Advances in Polymer Science, 1990, , 107-146.	0.4	15
50	Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma. International Journal of Hyperthermia, 1991, 7, 7-17.	1.1	15
51	Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma. Urology, 1991, 37, 288-294.	0.5	16
52	Selective Regional Chemotherapy of Unresectable Hepatic Tumours Using Lipiodol. HPB Surgery, 1991, 4, 223-236.	2.2	17
53	Neocarzinostatin: Selective tryptophan oxidation and neocarzinostatin-chromophore binding to apo-neocarzinostatin.. Chemical and Pharmaceutical Bulletin, 1991, 39, 170-176.	0.6	11
54	The significance of serum mitochondrial aspartate aminotransferase activity in the surgical field. The Japanese Journal of Surgery, 1991, 21, 14-24.	0.2	0
55	SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Advanced Drug Delivery Reviews, 1991, 6, 181-202.	6.6	211

#	ARTICLE	IF	CITATIONS
56	Kinin-generating Cascade in Advanced Cancer Patients and in vitro Study. Japanese Journal of Cancer Research, 1991, 82, 732-741.	1.7	99
57	Granulomatous Arteritis with Massive Eosinophilic Leukocyte Infiltration and Transient Peripheral Eosinophilia Subsequent to Transarterial Embolization Therapy with a Gelatin Sponge. Pathology International, 1991, 41, 618-622.	0.6	9
58	Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a western comparative study in 60 patients. Hepatology, 1991, 13, 427-433.	3.6	135
59	Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer, 1991, 67, 385-391.	2.0	125
60	A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer, 1991, 68, 2555-2560.	2.0	49
61	Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chemistry, 1992, 3, 351-362.	1.8	535
62	Cholestatic hepatocellular carcinoma diagnosed by deposits of Lipiodol and treated by combination of endoscopic retrograde biliary drainage and transcatheter arterial embolization. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 154-156.	1.4	5
63	Targeting chemotherapy for hepatoma: Arterial administration of anticancer drugs dissolved in lipiodol. European Journal of Cancer, 1992, 28, 403-409.	1.3	72
64	The tumor blood vessel as an ideal target for macromolecular anticancer agents. Journal of Controlled Release, 1992, 19, 315-324.	4.8	76
65	Original article: Evaluation of oil-soluble FUDR ester for transcatheter arterial treatment of hepatomas. Annals of Oncology, 1992, 3, 367-370.	0.6	5
66	Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma ? a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first) Tj ETQq0 0 0 rgBT /Overlock 10.1150 337	1.1	150
67	Clinicopathological study on combination therapy consisting of arterial infusion of lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 1992, 31, S7-S12.	1.1	35
68	Treatment of hepatocellular carcinoma with a CDDP-epirubicin-lipiodol suspension: a pilot clinico-pharmacological study. Cancer Chemotherapy and Pharmacology, 1992, 31, S51-S54.	1.1	14
69	Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 1992, 31, S55-S59.	1.1	20
70	Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution. Cancer Chemotherapy and Pharmacology, 1992, 31, S128-S136.	1.1	20
71	Transcatheter arterial embolization of hepatic neoplasms. Critical Reviews in Oncology/Hematology, 1992, 13, 93-105.	2.0	9
72	Preparation of [ <sup>131</sup> I]lipiodol as a hepatoma therapeutic agent. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 1992, 43, 1431-1435.	0.5	6
73	Therapeutic ethanol injection of hepatocellular carcinomas undetectable by angiography and lipiodol computed tomography. CardioVascular and Interventional Radiology, 1992, 15, 221-223.	0.9	5

#	ARTICLE	IF	CITATIONS
74	Chemoembolization of hepatocellular carcinomas a study of the biodistribution and pharmacokinetics of doxorubicin. <i>Cancer</i> , 1992, 70, 585-590.	2.0	184
75	Blood supply and drug delivery to primary and secondary human liver cancers studied with in vivo bromodeoxyuridine labeling. <i>Cancer</i> , 1993, 71, 50-55.	2.0	34
76	Hepatoma. <i>Journal of Surgical Oncology</i> , 1993, 53, 40-45.	0.8	4
77	Non-surgical treatment of hepatocarcinoma. <i>Journal of Surgical Oncology</i> , 1993, 53, 104-111.	0.8	26
78	Immunomodulating activities of orally administered SMANCS, a polymer-conjugated derivative of the proteinaceous antibiotic neocarzinostatin, in an oily formulation. <i>International Journal of Immunopharmacology</i> , 1993, 15, 175-183.	1.1	6
79	Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. <i>British Journal of Cancer</i> , 1993, 67, 975-980.	2.9	98
80	Enhanced Antitumor Activity and Reduced Toxicity of 1,3-Bis(2-chloroethyl)-1-nitrosourea Administered in Lipid Microspheres to Tumor-bearing Mice. <i>Japanese Journal of Cancer Research</i> , 1993, 84, 1078-1085.	1.7	13
81	Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: Correlation between computed tomography and histopathology. <i>CardioVascular and Interventional Radiology</i> , 1993, 16, 209-213.	0.9	55
82	Renal vein to portal vein collaterals in three cases of renal cell carcinoma extending into the inferior vena cava: Consequences for chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 1993, 16, 189-192.	0.9	7
83	Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. <i>Clinical Radiology</i> , 1993, 47, 315-320.	0.5	46
84	Treatment of Hepatocellular Carcinoma by Intraarterial Injection of Adriamycin/Mitomycin C Oil Suspension (ADMOS) Alone or Combined with CIS-Diaminodichloroplatinum (CDDP). <i>Acta Radiologica</i> , 1993, 34, 388-391.	0.5	6
85	Usefulness of Hepatic Artery Injection of Iodized Oil and <sup>131</sup> I-Labeled Iodized Oil before the Therapeutic Decision in Hepatocellular Carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 1993, 28, 217-223.	0.6	9
86	Medical Treatment of Hepatocellular Carcinoma: Any Progress?. <i>Tumori</i> , 1994, 80, 315-326.	0.6	19
87	Targeted Chemotherapy for Unresectable Primary and Metastatic Liver Cancer. <i>Acta Oncologica</i> , 1994, 33, 133-137.	0.8	16
88	Lipiodolization for unresectable hepatocellular carcinoma: An analysis of 205 patients using univariate and multivariate analysis. <i>Journal of Surgical Oncology</i> , 1994, 56, 54-58.	0.8	24
89	Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year Study of 127 French Patients. <i>Cancer</i> , 1994, 74, 16-24.	2.0	177
90	Hepatic arterial chemotherapy for metastatic colorectal carcinoma. <i>British Journal of Cancer</i> , 1994, 69, 372-378.	2.9	45
91	Polymer Conjugates. <i>Clinical Pharmacokinetics</i> , 1994, 27, 290-306.	1.6	155

#	ARTICLE	IF	CITATIONS
92	A chemotherapy for hepatocellular carcinoma using liposome preparation including immunomodulator OK-432. <i>Folia Pharmacologica Japonica</i> , 1995, 106, 212-216.	0.1	0
93	Arterial-injection chemotherapy for hepatocellular carcinoma using monodispersed poppy-seed oil microdroplets containing fine aqueous vesicles of epirubicin. Initial medical application of a membrane-emulsification technique. <i>Cancer</i> , 1995, 75, 1245-1254.	2.0	87
94	Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization. <i>Cancer</i> , 1995, 76, 736-742.	2.0	39
95	Randomized control trial of lipo-prostaglandin E1 in patients with acute liver injury induced by Lipiodol-targeted chemotherapy*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 582-589.	2.3	5
96	Transcatheter arterial chemoembolization therapy with epirubicin hydrochloride, mitomycin C-iohexol-Lipiodol emulsion (EMILE) for hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 1995, 30, 215-223.	2.3	7
97	Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats. <i>Heart and Vessels</i> , 1995, 10, 178-184.	0.5	39
98	Preparation and biodistribution of yttrium-90 Lipiodol in rats following hepatic arterial injection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 233-236.	2.2	26
99	Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer. <i>World Journal of Surgery</i> , 1995, 19, 795-800.	0.8	59
100	Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. <i>Critical Reviews in Oncology/Hematology</i> , 1995, 18, 207-231.	2.0	113
101	Coupled-column liquid chromatographic analysis of epirubicin and metabolites in biological material and its application to optimization of liver cancer therapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1995, 13, 615-623.	1.4	44
102	Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: Interim results of a phase I trial. <i>Annals of Surgical Oncology</i> , 1995, 2, 351-359.	0.7	2
103	Optimal formulation of an angiogenesis inhibitor, TNP-470, for arterial injection determined by in vitro drug release and stability, and in vivo antitumor activity. <i>International Journal of Pharmaceutics</i> , 1995, 123, 237-245.	2.6	5
104	Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma. <i>Pharmaceutical Research</i> , 1995, 12, 653-657.	1.7	14
105	Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. <i>European Journal of Cancer</i> , 1995, 31, 766-770.	1.3	328
106	Transcatheter Arterial Chemoembolization in Inoperable Hepatocellular Carcinoma: Four-year Follow-up. <i>Journal of Vascular and Interventional Radiology</i> , 1996, 7, 419-425.	0.2	44
107	Biodistribution of rhenium-188 Lipiodol infused via the hepatic artery of rats with hepatic tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 13-17.	2.2	46
108	Application of lipid microspheres for the treatment of cancer. <i>Advanced Drug Delivery Reviews</i> , 1996, 20, 209-219.	6.6	31
109	Targeted cancer chemotherapy with arterial microcapsule chemoembolization: review of 1013 patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 289-296.	1.1	47



#	ARTICLE	IF	CITATIONS
110	Radiolabelling of lipiodol with generator-produced $^{188}\text{Re}$ for hepatic tumor therapy. <i>Applied Radiation and Isotopes</i> , 1996, 47, 267-271.	0.7	32
111	Intra-Hepatic Arterial Drug Delivery. <i>Journal of Drug Targeting</i> , 1996, 3, 341-347.	2.1	21
112	Effect of arterial administration of a high molecular weight anti-tumor agent, styrene maleic acid neocarzinostatin, for multiple small liver cancer—A pilot study. <i>Journal of Gastroenterology</i> , 1997, 32, 513-520.	2.3	12
113	Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues. <i>Japanese Journal of Cancer Research</i> , 1998, 89, 307-314.	1.7	431
115	Stable lipiodolized emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolization. <i>Journal of Controlled Release</i> , 1998, 50, 135-143.	4.8	31
116	Targeted cancer chemotherapy for VX2 tumour implanted in the colon with lipiodol as a carrier. <i>European Journal of Cancer</i> , 1998, 34, 1764-1769.	1.3	16
117	Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma. <i>Oncology</i> , 1998, 55, 276-283.	0.9	27
118	In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines. <i>British Journal of Cancer</i> , 1999, 79, 1665-1671.	2.9	20
119	New oily agents for targeting chemoembolization for hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , 1999, 22, 130-134.	0.9	14
120	Effect of arterial administration of a high-molecular weight antitumor agent, styrene maleic acid neocarzinostatin, in embolization-resistant liver cancer. <i>International Journal of Clinical Oncology</i> , 1999, 4, 148-155.	1.0	2
121	In Vitro Release of SM-11355, cis-[[((1R,2R)-1,2-Cyclohexanediamine-N,N')bis(myristato)] Platinum(II) Suspended in Lipiodol.. <i>Biological and Pharmaceutical Bulletin</i> , 2000, 23, 637-640.	0.6	27
122	Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma. , 2000, 88, 1574-1581.		43
123	In vitro Antitumor Activity, Intracellular Accumulation, and DNA Adduct Formation of cis-[[((1R,2R)-1,2-Cyclohexanediamine-N,N')bis(myristato)] Platinum(II) Suspended in Lipiodol. <i>Cancer Research</i> , 2000, 91, 99-104.	1.7	10
124	Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. <i>Journal of Controlled Release</i> , 2000, 65, 271-284.	4.8	5,797
125	Focal therapeutic efficacy of transcatheter arterial infusion of styrene maleic acid neocarzinostatin for hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2000, 35, 28-33.	2.3	10
126	Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2000, 35, 353-360.	2.3	15
127	Comparison of CT Findings with Resected Specimens After Chemoembolization with Iodized Oil for Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2000, 175, 699-704.	1.0	212
128	A new assay for lipiodol in a tumor using a combination of m-chloroperbenzoic acid-mediated oxidation and the iodo-starch reaction. <i>Cancer Letters</i> , 2000, 158, 93-98.	3.2	7



#	ARTICLE	IF	CITATIONS
129	Tumor-targeted chemotherapy with SMANCS in lipiodol for renal cell carcinoma: longer survival with larger size tumors. <i>Urology</i> , 2000, 55, 495-500.	0.5	38
130	The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. <i>Advances in Enzyme Regulation</i> , 2001, 41, 189-207.	2.9	2,132
131	Long-term Prognosis of Patients Undergoing Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Comparison of Cisplatin Lipiodol Suspension and Doxorubicin Hydrochloride Emulsion. <i>Journal of Vascular and Interventional Radiology</i> , 2001, 12, 847-854.	0.2	74
132	Value of Lipiodol Computed Tomography and Digital Subtraction Angiography in the Era of Helical Biphasic Computed Tomography as Preoperative Assessment of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2001, 234, 56-62.	2.1	33
133	Hepatocellular carcinoma. <i>Annals of Oncology</i> , 2001, 12, 161-172.	0.6	92
134	Multiple hepatic infarction after transcatheter arterial infusion with SMANCS. <i>Journal of Gastroenterology</i> , 2001, 36, 415-421.	2.3	6
135	Efficient and cancer-selective gene transfer to hepatocellular carcinoma in a rat using adenovirus vector with iodized oil esters. <i>Cancer Gene Therapy</i> , 2001, 8, 713-718.	2.2	22
136	Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. <i>Journal of Controlled Release</i> , 2001, 74, 47-61.	4.8	861
137	SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. <i>Advanced Drug Delivery Reviews</i> , 2001, 46, 169-185.	6.6	514
138	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2001, 85, 1850-1852.	2.9	36
139	Targeted Transarterial Oily Chemoembolization for Small Foci of Hepatocellular Carcinoma Using a Unified Helical CT and Angiography system. <i>American Journal of Roentgenology</i> , 2001, 176, 681-688.	1.0	140
140	Synthesis and Biological Evaluation of Peg-Substituted Macromolecular Prodrugs of Mitomycin C. <i>Journal of Bioactive and Compatible Polymers</i> , 2002, 17, 123-138.	0.8	7
141	Arterial Embolization of Unresectable Hepatocellular Carcinoma with Use of Cyanoacrylate and Lipiodol. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, 61-69.	0.2	24
142	Predisposing Factors of Bile Duct Injury after Transcatheter Arterial Chemoembolization (TACE) for Hepatic Malignancy. <i>CardioVascular and Interventional Radiology</i> , 2002, 25, 270-274.	0.9	66
143	Where we go with hepatocellular carcinoma: past, present, and future perspectives. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2002, 9, 683-685.	2.0	7
144	Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. <i>Hepatology Research</i> , 2002, 23, 202-210.	1.8	41
145	Incidence and clinical outcome of icteric type hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 190-195.	1.4	71
146	Angiographic subsegmentectomy for the treatment of patients with small hepatocellular carcinoma. <i>Cancer</i> , 2003, 97, 1051-1056.	2.0	23

#	ARTICLE	IF	CITATIONS
147	Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. <i>British Journal of Cancer</i> , 2003, 89, 1614-1619.	2.9	43
148	Macromolecular Therapeutics. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1089-1105.	1.6	260
149	Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. <i>International Immunopharmacology</i> , 2003, 3, 319-328.	1.7	462
150	Non-Surgical Treatment Options in Hepatocellular Carcinoma. <i>Cancer Reviews: Asia-Pacific</i> , 2003, 01, 245-279.	0.1	1
151	Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinomas: Comparison of the Radiofrequency Effect With and Without Chemoembolization. <i>American Journal of Roentgenology</i> , 2003, 181, 997-1003.	1.0	100
152	A new technique for labeling of Lipiodol with <sup>188</sup> Re in the treatment of hepatic tumor. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2004, 261, 189-193.	0.7	7
153	Chemoembolization for hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, S179-S188.	0.6	504
154	Factors and Mechanism of EPR Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS. , 2003, 519, 29-49.		188
155	Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection. <i>Nuclear Medicine and Biology</i> , 2004, 31, 671-677.	0.3	23
156	Stable paclitaxel formulations in oily contrast medium. <i>Journal of Controlled Release</i> , 2005, 102, 415-425.	4.8	25
157	The EPR Effect and Polymeric Drugs: A Paradigm Shift for Cancer Chemotherapy in the 21st Century. <i>Advances in Polymer Science</i> , 2005, , 103-121.	0.4	135
158	Hepatic Arterial Chemoembolization for Hepatocellular Carcinoma: Comparison of Survival Rates with Different Embolic Agents. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1661-1666.	0.2	92
159	Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients. <i>Gastroenterology</i> , 2006, 131, 461-469.	0.6	733
160	Adenovirus Vector-Mediated Gene Transfer Using Degradable Starch Microspheres for Hepatocellular Carcinoma in Rats. <i>Journal of Surgical Research</i> , 2006, 133, 193-196.	0.8	18
161	Transarterial Chemoembolization as a Bridge to Liver Transplantation for Hepatocellular Carcinoma: An Evidence-Based Analysis. <i>American Journal of Transplantation</i> , 2006, 6, 2644-2650.	2.6	163
162	Transcatheter Arterial Chemoembolization: Current Technique and Future Promise. <i>Techniques in Vascular and Interventional Radiology</i> , 2007, 10, 2-11.	0.4	63
163	Pilot Study of Combination Therapy With Transcatheter Arterial Infusion Chemotherapy Using Iodized Oil and Percutaneous Radiofrequency Ablation During Occlusion of Hepatic Blood Flow for Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 311-316.	0.6	10
164	Principles of Embolization. , 2008, , 67-77.		0

#	ARTICLE	IF	CITATIONS
165	Transcatheter Arterial Chemoembolization: Technique and Future Potential. , 2008, , 192-201.		1
166	Pharmacology and Therapeutic Applications of Eneidiyne Antitumor Antibiotics. Current Molecular Pharmacology, 2008, 1, 50-60.	0.7	49
167	Impact of a Unified CT Angiography System on Outcome of Patients with Hepatocellular Carcinoma. American Journal of Roentgenology, 2009, 192, 766-774.	1.0	33
168	Transarterial Infusion Chemotherapy Using Cisplatin-Lipiodol Suspension With or Without Embolization for Unresectable Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2009, 32, 687-694.	0.9	23
169	Lipid-based systemic delivery of siRNA. Advanced Drug Delivery Reviews, 2009, 61, 721-731.	6.6	424
170	Elevating Blood Pressure as a Strategy to Increase Tumor-targeted Delivery of Macromolecular Drug SMANCS: Cases of Advanced Solid Tumors. Japanese Journal of Clinical Oncology, 2009, 39, 756-766.	0.6	156
171	Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 409-419.	2.0	1,055
172	Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology, 2009, 51, 1030-1036.	1.8	90
173	Effects of Hepatic Artery Chemoembolization Using Cisplatinâ€“lipiodol Suspension with Gelatin Sponge Particles on Swine Liver. Journal of Vascular and Interventional Radiology, 2009, 20, 1359-1364.	0.2	11
174	Chemoembolization for Primary and Metastatic Liver Cancer. Cancer Journal (Sudbury, Mass ), 2010, 16, 156-162.	1.0	33
175	Cerebral Lipiodol Embolism Proven by Dual-Energy Computed Tomography. Journal of Computer Assisted Tomography, 2010, 34, 105-106.	0.5	7
176	Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand?. Annals of Surgical Oncology, 2010, 17, 1234-1246.	0.7	80
177	Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma. Japanese Journal of Radiology, 2010, 28, 362-368.	1.0	26
178	Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today, 2010, 5, 296-312.	6.2	98
179	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. Hpb, 2010, 12, 313-320.	0.1	68
180	<i>In vitro</i> and <i>in vivo</i> evaluation of tumor targeting styreneâ€“maleic acid copolymerâ€“pirarubicin micelles: Survival improvement and inhibition of liver metastases. Cancer Science, 2010, 101, 1866-1874.	1.7	49
181	Effect of sodium thiosulfate on cisplatin removal after intra-arterial embolization with a lipiodol-platinum suspension for hepatocellular carcinoma. Acta Radiologica, 2010, 51, 383-388.	0.5	6
182	Hypersensitivity Reactions to Transcatheter Chemoembolization with Cisplatin and Lipiodol Suspension for Unresectable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2010, 21, 1219-1225.	0.2	15

#	ARTICLE	IF	CITATIONS
184	Use of lipid microspheres as a drug carrier for antitumour drugs. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 38, 132-134.	1.2	32
185	Targeted drug delivery to tumors: Myths, reality and possibility. <i>Journal of Controlled Release</i> , 2011, 153, 198-205.	4.8	1,580
186	X-ray synthesized PEGylated (polyethylene glycol coated) gold nanoparticles in mice strongly accumulate in tumors. <i>Materials Chemistry and Physics</i> , 2011, 126, 352-356.	2.0	25
187	Double Targeting of Tumours with Pyrenyl-Modified Dendrimers Encapsulated in an Arene-Ruthenium Metallaprism. <i>Chemistry - A European Journal</i> , 2011, 17, 1966-1971.	1.7	83
188	Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. <i>Indian Journal of Radiology and Imaging</i> , 2011, 21, 113-120.	0.3	31
189	Transcatheter Intraarterial Therapies: Rationale and Overview. <i>Radiology</i> , 2011, 259, 641-657.	3.6	206
190	Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan. <i>Cancers</i> , 2012, 4, 165-183.	1.7	26
191	Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 247-255.	0.6	39
192	Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2012, 88, 53-71.	1.6	233
193	Nitroglycerine use in transcatheter arterial (chemo)embolization in patients with hepatocellular carcinoma and dual-energy CT assessment of Lipiodol retention. <i>European Radiology</i> , 2012, 22, 2193-2200.	2.3	24
194	Comparison of Epirubicin-Iodized Oil Suspension and Emulsion for Transcatheter Arterial Chemoembolization in VX2 Tumor. <i>Scientific World Journal, The</i> , 2012, 2012, 1-7.	0.8	8
195	Interventional therapies for hepatocellular carcinoma. <i>Cancer Imaging</i> , 2012, 12, 79-88.	1.2	26
196	Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. <i>Journal of Controlled Release</i> , 2012, 161, 338-350.	4.8	96
197	Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1343-1350.	1.9	83
198	Challenges for Metals in Medicine: How Nanotechnology May Help To Shape the Future. <i>ACS Nano</i> , 2013, 7, 5654-5659.	7.3	132
199	The link between infection and cancer: Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. <i>Cancer Science</i> , 2013, 104, 779-789.	1.7	143
200	The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 71-79.	6.6	1,960
201	Hepatic embolotherapy in interventional oncology: Technology, techniques, and applications. <i>Clinical Radiology</i> , 2013, 68, 1-15.	0.5	35

#	ARTICLE	IF	CITATIONS
202	Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 530-549.	2.0	167
203	Synthesis of Longâ€Circulating, Backbone Degradable HEMA Copolymerâ€Doxorubicin Conjugates and Evaluation of Molecularâ€Weightâ€Dependent Antitumor Efficacy. <i>Macromolecular Bioscience</i> , 2013, 13, 155-160.	2.1	54
204	Nanomedicine Treatment Strategies That Exploit Unique Characteristics of Tumor Vasculature and Microenvironment. , 2013, , 175-186.		0
205	Effect of Transcatheter Intraarterial Therapies on the Distribution of Doxorubicin in Liver Cancer in a Rabbit Model. <i>PLoS ONE</i> , 2013, 8, e76388.	1.1	25
206	Comparison of Drug Release and Pharmacokinetics after Transarterial Chemoembolization Using Diverse Lipiodol Emulsions and Drug-Eluting Beads. <i>PLoS ONE</i> , 2014, 9, e115898.	1.1	56
207	Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. <i>Tumor Biology</i> , 2014, 35, 10905-10910.	0.8	15
208	Computed tomography of Lipiodolâ€Loaded biodegradable pasty polymer for implant visualization. <i>Contrast Media and Molecular Imaging</i> , 2014, 9, 246-251.	0.4	4
209	Pluronicâ„R block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances. <i>Polymer Chemistry</i> , 2014, 5, 3291-3297.	1.9	369
210	EPR: Evidence and fallacy. <i>Journal of Controlled Release</i> , 2014, 190, 451-464.	4.8	640
211	Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S112-S121.	0.4	24
212	Rationale of transcatheter intra-arterial therapies of hepatic cancers. <i>Hepatic Oncology</i> , 2014, 1, 285-291.	4.2	2
215	MRI-detectable polymeric micelles incorporating platinum anticancer drugs enhance survival in an advanced hepatocellular carcinoma model. <i>International Journal of Nanomedicine</i> , 2015, 10, 4137.	3.3	11
216	Transarterial approaches to primary and secondary hepatic malignancies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 481-489.	12.5	37
217	Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 53-64.	2.4	193
219	Arene ruthenium dithiolatoâ€carborane complexes for boron neutron capture therapy (BNCT). <i>Journal of Organometallic Chemistry</i> , 2015, 796, 17-25.	0.8	27
220	Synthesis and characterization of image-able polyvinyl alcohol microspheres for image-guided chemoembolization. <i>Journal of Materials Science: Materials in Medicine</i> , 2015, 26, 198.	1.7	37
221	Transarterial chemoembolization (TACE) for colorectal liver metastasesâ€current status and critical review. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 641-659.	0.8	55
222	Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 607-615.	1.8	20

#	ARTICLE	IF	CITATIONS
223	Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. <i>British Journal of Radiology</i> , 2015, 88, 20140564.	1.0	26
224	Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. <i>American Journal of Roentgenology</i> , 2015, 205, 764-773.	1.0	27
225	Cancer targeted therapeutics: From molecules to drug delivery vehicles. <i>Journal of Controlled Release</i> , 2015, 219, 632-643.	4.8	89
226	Conventional chemoembolization and chemoembolization with drug-eluting beads: Technique and future potential. , 0, , 120-127.		0
227	Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 68.	1.7	46
228	A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next Generation Chemotherapeutics and Photodynamic Therapy Problems, Solutions, and Prospects. <i>Microcirculation</i> , 2016, 23, 173-182.	1.0	273
229	Interventional oncology for hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 530-537.	0.7	9
230	The Tumor Microenvironment as a Barrier to Cancer Nanotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 936, 165-190.	0.8	18
231	A multifunctional contrast dye for morphological research. <i>Microscopy Research and Technique</i> , 2016, 79, 111-121.	1.2	1
232	Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?. <i>Hepatic Oncology</i> , 2016, 3, 109-118.	4.2	4
233	Transcatheter intra-arterial infusion of doxorubicin loaded porous magnetic nano-clusters with iodinated oil for the treatment of liver cancer. <i>Biomaterials</i> , 2016, 88, 25-33.	5.7	51
234	Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 334-343.	0.9	198
235	Selective boron delivery by intra-arterial injection of BSH-WOW emulsion in hepatic cancer model for neutron capture therapy. <i>British Journal of Radiology</i> , 2017, 90, 20170004.	1.0	13
236	Nanomedicine for prostate cancer using nanoemulsion: A review. <i>Journal of Controlled Release</i> , 2017, 260, 111-123.	4.8	38
237	The value of paradoxical uptake of hepatocellular carcinoma on the hepatobiliary phase of gadoxetic acid-enhanced liver magnetic resonance imaging for the prediction of lipiodol uptake after transcatheter arterial chemoembolization. <i>European Journal of Radiology</i> , 2017, 89, 169-176.	1.2	3
238	New concepts in embolotherapy of HCC. <i>Medical Oncology</i> , 2017, 34, 58.	1.2	53
239	New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. <i>Journal of Controlled Release</i> , 2017, 268, 184-197.	4.8	33
240	Conjugate Polyplexes with Anti-Invasive Properties and Improved siRNA Delivery In Vivo. <i>Bioconjugate Chemistry</i> , 2018, 29, 296-305.	1.8	10



#	ARTICLE	IF	CITATIONS
241	Liver chemoembolization of hepatocellular carcinoma using TANDEM <sup>®</sup> microspheres. <i>Future Oncology</i> , 2018, 14, 2761-2772.	1.1	15
242	Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2018, 18, 124.	0.8	33
243	Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 542-552.	0.7	4
244	Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 983-1014.	1.6	17
245	Other Endovascular Procedures and Embolization. , 2020, , 273-285.		0
246	Overcoming barriers for tumor-targeted drug delivery. , 2020, , 41-58.		7
247	<p>&lt;p>Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma</p></p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5029-5041.	2.0	7
248	Transarterial chemoembolization for hepatocellular carcinoma: a bibliometric analysis of the most cited articles. <i>Japanese Journal of Radiology</i> , 2020, 38, 1190-1196.	1.0	4
249	Multi-energy computed tomography and material quantification: Current barriers and opportunities for advancement. <i>Medical Physics</i> , 2020, 47, 3752-3771.	1.6	14
250	Liver-directed therapy for hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 8-8.	0.4	8
251	Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , 2021, 69, 91-99.	4.3	33
252	Characterization of Magnetite/Iodized Oil Magnetic Fluid for Embolization and Hyperthermia Application. <i>Journal of Superconductivity and Novel Magnetism</i> , 2021, 34, 1165-1176.	0.8	2
253	Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 199-212.	2.4	33
254	Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water Emulsion <i>In Vivo</i> . <i>In Vivo</i> , 2021, 35, 239-248.	0.6	1
255	The 35th Anniversary of the Discovery of EPR Effect: A New Wave of Nanomedicines for Tumor-Targeted Drug Delivery—Personal Remarks and Future Prospects. <i>Journal of Personalized Medicine</i> , 2021, 11, 229.	1.1	87
256	The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. <i>Journal of Personalized Medicine</i> , 2021, 11, 771.	1.1	275
257	Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma — The Changing Tides. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1089-1115.	1.8	28
258	Alternative Treatment Approaches to Early Stage or Unresectable Hepatocellular Carcinoma Confined to the Liver. , 1998, , 79-94.		3



#	ARTICLE	IF	CITATIONS
259	Regional Chemotherapy of Liver Cancer. , 1985, , 247-261.		5
260	Enhanced Permeability and Retention (EPR) Effect: Basis for Drug Targeting to Tumor. , 2002, , 211-228.		11
261	The Eneidyne. , 1997, , 229-240.		2
262	Medical Therapy of HCC. , 2016, , 489-512.		1
263	Metamorphosis of Neocarzinostatin to SMANCS: Chemistry, Biology, Pharmacology, and Clinical Effect of the First Prototype Anticancer Polymer Therapeutic. , 1997, , 227-267.		20
264	Hepatic angiography in hepatocellular carcinoma: status among modern imaging modalities and its role as a further examination. , 1992, , 153-160.		2
265	Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. , 1992, , 259-271.		17
266	Small Hepatocellular Carcinoma. , 1987, , 215-226.		21
267	Targeting Chemotherapy of Hepatocellular Carcinoma. , 1987, , 343-352.		20
268	A revised primary structure for neocarzinostatin based on fast atom bombardment and gas chromatographic-mass spectrometry.. Journal of Biological Chemistry, 1984, 259, 10801-10806.	1.6	32
269	Imaging and Hepatocellular Carcinoma. Gastroenterology Clinics of North America, 1987, 16, 591-602.	1.0	14
270	Medical Treatment of Hepatocellular Carcinoma. Gastroenterology Clinics of North America, 1987, 16, 603-612.	1.0	28
271	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. , 0, .		1
272	Long-Term Results of Lipiodol-Transcatheter Arterial Embolization With Cisplatin or Doxorubicin for Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 564-568.	0.6	71
274	Intra-hepatic artery injectional chemotherapy with suspension of cisplatin in lipiodol for hepatocellular carcinoma.. Drug Delivery System, 1988, 3, 431-435.	0.0	4
275	Diagnostic values and therapeutic effects of transcatheter arterial embolization using Lipiodol (Lp-TAE) for hepatocellular carcinoma. Comparison of medical images and resected specimens.. Acta Hepatologica Japonica, 1986, 27, 28-35.	0.0	3
276	Clinico-pathologic study on selective accumulation of Lipiodol, an oily contrast medium, in hepatocellular carcinoma.. Acta Hepatologica Japonica, 1986, 27, 471-479.	0.0	4
277	Treatment of advanced hepatocellular carcinoma with hepatic artery infusion of SMANCS-Lipiodol.. Acta Hepatologica Japonica, 1989, 30, 898-903.	0.0	1

#	ARTICLE	IF	CITATIONS
278	Studies on the effect of lipiodol during transcatheter arterial embolization for liver tumor.. Acta Hepatologica Japonica, 1990, 31, 636-646.	0.0	1
279	Prospective Study on the Survival of HCC Patients Treated with Transcatheter Arterial Lipiodol Chemoembolization. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1039-1042.	0.5	10
280	Paradigm shift in dosage determination of anticancer agents.. Drug Delivery System, 2002, 17, 88-93.	0.0	0
281	MACROMOLECULAR CARRIERS FOR DRUG TARGETING. , 2003, , 587-600.		0
282	Embolization of Liver Tumors. , 2007, , 1218-1245.		1
283	Nano DDS. Oleoscience, 2007, 7, 99-103.	0.0	0
284	Medical Therapy of HCC. , 2009, , 527-568.		0
287	Embolotherapy in the Management of Gynecologic Neoplasms. , 2013, , 781-787.		0
289	A NEW THERAPY FOR HEPATIC MALIGNANT TUMORS. The KITAKANTO Medical Journal, 1986, 36, 367-371.	0.0	0
290	Multicentric & hypovascular hepatocellular carcinoma and its relationship to pathological findings.. Acta Hepatologica Japonica, 1986, 27, 802-809.	0.0	0
291	Diagnostic and Interventional Radiology of Liver Tumors. , 1988, , 832-834.		0
292	Dosimetry study of tumor with I-131-Lipiodol paraffin phantoms. Journal of the Korean Radiological Society, 1988, 24, 330.	0.0	0
293	An assessment of four-year survived unresectable hepatocellular carcinoma: A comparative study with the cases which died within two years after treatment.. Acta Hepatologica Japonica, 1989, 30, 1606-1616.	0.0	0
294	Clinical study on hepatic angiography after hepatectomy in patients with hepatocellular carcinoma.. Japanese Journal of Gastroenterological Surgery, 1989, 22, 791-797.	0.0	0
295	Targeting chemotherapy using lipiodol as a carrier of anticancer drugs for hepatocellular carcinoma and metastatic liver cancer.. Drug Delivery System, 1989, 4, 36-40.	0.0	0
296	Targeted Therapy of Liver Carcinoma. , 1990, , 127-135.		0
297	Multimodal treatment including N-cws/lipiodol immunotherapy for hepatocellular carcinomas. Its safety and therapeutic efficacy.. Japanese Journal of Gastroenterological Surgery, 1990, 23, 1062-1070.	0.0	0
298	Regionale Therapie bei hepatozellulÄrem Karzinom. , 1991, , 121-131.		0

#	ARTICLE	IF	CITATIONS
300	Selektive Chemoembolisation von primären und sekundären Lebermalignomen mit Mitomycin C, Lipiodol und Dura. , 1991, , 73-85.		1
301	Assessment of five-year survivors with unresectable hepatocellular carcinoma treated by transcatheter arterial embolization(TAE) combined with Lipiodol.. Acta Hepatologica Japonica, 1992, 33, 541-547.	0.0	0
302	Chemoembolization of the Liver: Results of More than 300 Embolization Procedures. , 1993, , 221-230.		1
303	CLINICAL EVALUATION OF PREOPERATIVE HEPATIC ARTERIAL INFUSION CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA. The Journal of the Japanese Practical Surgeon Society, 1993, 54, 1474-1479.	0.0	0
304	Chemotherapie maligner gastrointestinaler Tumoren. Angewandte Onkologie, 1995, , 239-272.	0.0	0
305	Strategies for Dealing With the Immunogenicity of Therapeutic Proteins. Handbook of Experimental Pharmacology, 1999, , 59-88.	0.9	1
306	Recent technical advances in conventional transarterial chemoembolization for hepatocellular carcinoma in Japan. International Journal of Gastrointestinal Intervention, 2021, 10, 152-160.	0.1	2
307	Locoregional Therapy: Cancer Interventions with and Without Radionuclides. , 2021, , 89-109.		0
308	Physics and Physiology of Transarterial Chemoembolization and Drug-Eluting Beads for Liver Tumors. , 2020, , 29-42.		1
309	Research and Future Directions in Oncology Embolotherapy. , 2006, , 221-232.		0
310	Regional Therapy of Pancreatic Cancer. , 2007, , 303-312.		0
312	Interventional oncology of liver tumors: how it all started and where are we now. British Journal of Radiology, 2022, 95, .	1.0	1
313	35 years of discussions with Prof. Maeda on the EPR effect and future directions. Journal of Controlled Release, 2022, 348, 966-969.	4.8	9
314	Selective Enhancing Blood Flow in Solid Tumor Tissue Is the Key for Achieving Satisfactory Delivery and Therapeutic Outcome of Nanodrugs via the EPR Effect. Journal of Personalized Medicine, 2022, 12, 1802.	1.1	0